We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Kady
Hutton
ras@uhb.nhs.uk
Claire
Butler
c.e.butler@bham.ac.uk
Dr
Andrew
Filer
a.filer@bham.ac.uk
Mr
Joe
Golby
joe.golby@nihr.ac.uk
Ms
Hollie
Caulfield
bioresstudy@contacts.bham.ac.uk
Inflammatory polyarthropathies
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Rheumatoid Arthritis (RA) is a condition that causes joint inflammation which leads to joint deformity and long-term disability. It affects 580,000 adults in England and costs £1.8 billion per year to the UK economy due to work-related disability.
Biologic treatments are available for patients with severe disease who do not respond to first-line anti-rheumatic medications. However, only a proportion of patients with inflammatory arthritis respond to these expensive treatments, which results in unnecessary treatment and significant cost to the National Health Service. Therefore, identifying the group of patients who will respond to biologic therapy will allow doctors to target this treatment to the most appropriate group of patients.
We aim to
1. Assess new predictors of response to biologic treatment in patients with inflammatory arthritis
2. Understand mechanisms operating in the joints of patients with inflammatory arthritis who respond to treatment with biologic therapy
3. Assess the cost-effectiveness of identifying the group of patients who are likely to respond to biologic treatment
We will scan patients with inflammatory arthritis using a non-invasive
near patient ultrasound scanner and novel techniques for imaging of joints, and take biological samples of serum, urine and stool to identify those who are likely to respond to biologic treatment. Samples will be analysed using high throughput omics technologies including NMR metabolomics.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
1. Treatment with biologic therapy prior to assessment 2. Age <18 years
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Mr
Joe
Golby
joe.golby@nihr.ac.uk
Claire
Butler
c.e.butler@bham.ac.uk
Dr
Andrew
Filer
a.filer@bham.ac.uk
Ms
Hollie
Caulfield
bioresstudy@contacts.bham.ac.uk
Kady
Hutton
ras@uhb.nhs.uk
The study is sponsored by University of Birmingham and funded by VERSUS ARTHRITIS; Medical Research Council (MRC); .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 17508
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
